INVESTORS DATABASE

Investor Number of Investments Headquarters (City) Headquarters (Country) Year Founded Total Investents, $M Stages Sectors Investments in Longevity Companies Related Investments
ABN AMRO Unknown Amsterdam Netherlands 1991 6950.00 Unknown Fintech 100k-1M Color Genomics: $15M Series A in April 2015 with 13 other investors (AaronLevie, AME Cloud Ventures, Drew Houston, Formation 8, Julia Hartz, Kati Stanton, Khosla ventures, Laurene Powell Jobs, Mariam Naficy, Max Levchin,
Padmasree Warrior, Raymond Tonsing, Ruchi Sanghvi
Accuitive Medical Ventures 45.00 Duluth USA Unknown 0.00 Seed, Early Stage, Late Stage, Debt Financing Healthcare, Biotechnology, Medical Devices Unknown AxoGen - 12.1M Post-IPO Equity in December 2007 with 3 other investors
(Springboard Capital, Cardinal Partners and Denovo Ventures)
Advantech Capital 4.00 Unknown China 2015 215.00 Early Stage,
Late Stage
Technology,
 Healthcare,
Media and
Communications
$15M-$100M Harbour BioMed - $50M (Series A) in Dec, 2016 with 1 other investor
(Advantech Capital, Legend Capital)
Alexandria Venture 28.00 San Francisco USA Unknown 0.00 Early Stage Biotechnology Unknown Editas Medicine - $120M (Series B) in Aug, 2015 with 14 other investors
(Boris Nikolic, Casdin Capital, Deerfield, EcoR1 Capital, Fidelity Management
and Research Company, Flagship pioneering, GV, Jennison associates,
Khosla Ventures, Omega funds, Polaris partners, T. Rowe Price, Third Rock
Ventures, Viking Global Investors)
Ally Bridge Group 12.00 Hong Kong, HK Island China 2013 264.07 Early Stage, Late Stage, Private Equity, Secondary Market, Post IPO Biopharmaceuticals, Medical devices Unknown Hua Medicine - $25M Series B with 1 other investor (Venrock) in January 2015
ALS Finding a cure 2.00 Stamford, Connecticut USA Unknown 19.96 Unknown Healthcare Unknown Emulate Inc. - $17M (Series B) in October 2016 with 2 other investors (ATEL
Ventures, Cedars Sinai Medical Center)
AME Cloud Ventures 152.00 Palo Alto, California USA 2012 0.00 Seed, Early Stage, Late Stage Cloud Computing, Enterprise Software, Enterprises Unknown Emulate Inc. - $17M (Series B) in October 2016 with 6 other investors (ATEL
Ventures, Cedars Sinai Medical Center, Hansjorg Wyss, NanoDimension, OS
Fund, Techammer)
Amino Capital 56.00 Palo Alto, California USA 2012 0.00 Seed, Early Stage Big Data, Health IT, Genomics, Enterprise Software, Consumer
Hardware
200k-10M Human Longevity Inc.: $220M Series B with 5 other investors (Illumina, Celgene, Draper Fisher Jurvetson, GE Ventures, StartUp Health) in April 2016
Ann Arbor SPARK 89.00 Ann Arbor, Michigan USA 2005 0.00 Seed, Early Stage, Debt Financing Healthcare, IT, Social Media, Materials, Alt Energy Unknown Axonia Medical - $2M Seed in May 2012 with 1 other investor (SWMF Life
Sciences Fund)
ARCH Venture Partners 238.00 Chicago, Illinois USA 1986 0.00 Early Stage, Late Stage, Private Equity Biotechnology, Healthcare, Clean Technology Unknown Bluebird Bio - $60M (Series D) in Jul, 2012 from 6 other Investors (RA
Capital Management, Deerfield Partners, Third Rock Ventures, Forbion
Capital Partners, TVM Capital, Ramius Advisors); Bluebird Bio - $30M
(Venture) in Apr, 2011 from 4 other Investors (Third Rock Ventures, TVM
Capital, Forbion Capital Partners, Easton Capital, ARCH Venture Partners) ;
Hua Medicine - $50M Series A with 5 other investors (Eight Roads Ventures,
F-Prime Capital Partners, Sino-alliance International Ltd., Venrock, WuXi
Healthcare Ventures) in September 2011 ; Semma Therapeutics - $44M
Series A with 3 other investors (F-Prime Capital Partners, Medtronic, MPM
Capital)
Arkin Holdings 4.00 Tel Aviv, Tel Aviv Israel Unknown 0.00 Early Stage Healthcare $5M-$20M Metabomed - "$18M (Series A) in Apr, 2016 with 4 other investors (Boehringer Ingelheim Venture Fund, Merck Ventures, Pfizer, Pontifax Funds)
Aspire Capital Partners LLC 1.00 Chicago, Illinois USA Unknown 2.00 Unknown Biotechnology, Software Unknown Athersys Inc - $20M Post-IPO Equity in November 2011
ATEL Ventures 14.00 San Francisco, California USA 1999 0.00 Early Stage, Late Stage, Debt Financing IT, Life Sciences, Green Technologies 200k - 25M Emulate Inc. - $28M (Series B) in March 2016 with 2 other investors (OS
Fund, LabCorp); Emulate Inc. - $17M (Series B) in October 2016 with 6 other
investors (ALS Finding a Cure, ATEL Ventures, Cedars Sinai Medical Center,
Hansjorg Wyss, NanoDimension, OS Fund, Techammer)
Biosciences Research and Commercialization Center (BRCC) 3.00 Kalamazoo, Michigan USA 2003 4.00 Seed, Early Stage Biotechnology, Pharmaceuticals 1M-2M Axonia Medical - $2M Seed in June 2014 with 3 other investors (SWMF Life Science Fund, Research Emeritus, University of Michigan)
Brainchild Holdings 88.00 Newtown, Pennsylvania USA Unknown 0.00 Seed, Early Stage Healthcare, Hardware, Vertical Search, Sports 50k-5M Color Genomics $38.55M Venture in August 2016
Cardinal Partners 47.00 Princeton, New Jersey USA 1996 0.00 Early Stage, Late Stage Healthcare, Biotechnology, Wellbeing Unknown AxoGen - 12.1M Post-IPO Equity in December 2007 with 3 other investors
(Springboard Capital, Accuitive Medical Ventures and Denovo Ventures)
Casdin Capital 18.00 New York, New York USA 2011 0.00 Early Stage, Late Stage Healthcare, Biotechnology, Big Data Unknown Editas Medicine - $120M (Series B) in Aug, 2015 with 14 other investors
(Boris Nikolic, Alexandria Venture, Deerfield, EcoR1 Capital, Fidelity
Management and Research Company, Flagship pioneering, GV, Jennison
associates, Khosla Ventures, Omega funds, Polaris partners, T. Rowe Price,
Third Rock Ventures, Viking Global Investors)
Celgene 32.00 Summit, New Jersey USA 1986 0.00 Series Investment, Private Equity, Venture Therapeutics, Healthcare, Medical Unknown Human Longevity Inc. - $220M Series B with 5 other investors (Illumina,
Amino Capital, Draper Fisher Jurvetson, GE Ventures, StartUp Health) in
April 2016 ; Human Longevity Inc. - $80M Series A with 6 other investors
(Bryan Johnson, Daniel Curran, Draper Fisher Jurvetson, Illumina, Synthetic
Genomics, Tan Thay) in March 2014
CIRM 3.00 San Francisco, California USA 2005 0.00 Venture, Grant Biotechnology Unknown Bluebird Bio - $9.3M (Venture) in Oct, 2012 ; Semma Therapeutics - $5M Grant in September 2016
Cyberdyne 2.00 Ibaraki, Osaka Japan Unknown 14.95 Seed, Venture Hardware, Software Unknown Cyfuse Biomedical - $12M (Venture) in Mar, 2015 with 1 other investors
(Shibuya Kogyo)
Deep Knowledge Life Sciences 7.00 London UK 2014 100.00 Early Stage Regenerative Medicine, Artificial Intelligence, Big Data, Fintech Unknown InSilico Medicine - Undisclosed in Apr 2014 and Nov 2015;
Pathway Pharmaceuticals - Undisclosed in Apr 2014 and Aug, 2015.
Deerfield Partners 3.00 San Francisco, California USA Unknown 141.00 Late Stage Biotechnology, Healthcare Unknown Bluebird Bio - $60M (Series D) in July, 2012 with 6 other Investors (RA
Capital Management, Third Rock Ventures, ARCH Venture Partners, Forbion
Capital Partners, TVM Capital, Ramius Advisors)
DeNovo Ventures 88.00 Saratoga, California USA 200 0.00 Early Stage, Late Stage Biotechnology, Healthcare, Medical Devices Unknown AxoGen - 12.1M Post-IPO Equity in December 2007 with 3 other investors
(Springboard Capital, Accuitive Medical Ventures and Cardinal Partners)
Draper Fisher Jurvetson (DFJ) 782.00 Menlo Park, California USA 1985 0.00 Seed, Early Stage, Late Stage, Private Equity, Debt Financing Advertising, Mobile, Software Unknown Human Longevity Inc. - $220M Series B with 5 other investors (Illumina,
Amino Capital, Celgene, GE Ventures, StartUp Health) in April 2016; Human
Longevity Inc. - $80M Series A with 6 other investors (Bryan Johnson,
Celgene, Daniel Curran, Illumina, Synthetic Genomics, Tan Thay) in March
2014; Eve Biomedical - $1.67M (Seed) in April 2012; Eve Biomedical - $6M
(Series B) in December 2012; Vitruvian Networks - $12.81M Venture in
November 2016
Easton Capital 59.00 Unknown Unknown Unknown 0.00 Seed, Early Stage, Late Stage, Private Equity, Debt Financing Technology, Diagnostics, Medical Devices, Therapeutics $2M-$7.5M Bluebird Bio - $30M (Venture) in Apr, 2011 from 4 other Investors (Third
Rock Ventures, TVM Capital, Forbion Capital Partners, Easton Capital, ARCH
Venture Partners); Bluebird Bio - $35M(Series B) in Mar, 2010 from 4 other
Investors (TVM Capital, Forbion Capital Partners, Third Rock Ventures,
Sanofi-Genzyme BioVentures)
EcoR1 Capital 17.00 San Francisco, California USA 2012 0.00 Early Stage, Late Stage Biotechnology Unknown Editas Medicine - $120M (Series B) in Aug, 2015 with 14 other investors
(Boris Nikolic, Alexandria Venture, Casdin Capital, Deerfield, Fidelity
Management and Research Company, Flagship pioneering, GV, Jennison
associates, Khosla Ventures, Omega funds, Polaris partners, T. Rowe Price,
Third Rock Ventures, Viking Global Investors)
Eight Roads Ventures 91.00 London, England UK 1994 0.00 Seed, Early Stage, Late Stage, Private Equity, Post IPO Fintech, Big Data, Healthcare, Bioscience, Energy, Industrial
Technology
Unknown Hua Medicine - $50M Series A with 5 other investors (ARCH Venture
Partners, F-Prime Capital Partners, Sino-alliance International Ltd., Venrock,
WuXi Healthcare Ventures)
Emerson Collective 12.00 Walnut Creek, California USA 2004 0.00 Seed Genomics, Medical Unknown Color Genomics - $45M Series B in September 2016 with 2 other investors
(General Catalyst (Lead investor), Khosla Ventures)
Essex Woodlands Health Ventures 73.00 Palo Alto, California USA 1985 0.00 Early Stage, Late Stage, Private Equity, Debt Financing Biotechnology, Healthcare, Life Sciences Unknown AxoGen - $17.5M Post-IPO Equity in August 2015
Ferghana Partners Unknown Cambridge, Massachusetts USA 1946 0.00 Seed, Early Stage, Late Stage Healthcare, Technology Unknown Hua Medicine - $50M Series A with 5 other investors (ARCH Venture
Partners, Eight Roads Ventures, Sino-alliance International Ltd., Venrock,
WuXi Healthcare Ventures) ; Semma Therapeutics - $44M Series A with 3
other investors (ARCH Venture Partners, Medtronic, MPM Capital)
Fidelity Management and Research Company (Fidelity Investments) 87.00 New York, New York USA 1991 0.00 Partnering, Aquisitions, Divestments, Financings Medical Devices, Pharmaceuticals, Biotechnology, Specialty Chemicals, Diagnostics/Tools, OTC Drugs Unknown Unknown
First Analysis 29.00 Boston, Massachusetts USA 1946 0.00 Unknown Asset Management Unknown Editas Medicine - $120M (Series B) in Aug, 2015 with 14 other investors
(Boris Nikolic, Alexandria Venture, Casdin Capital, Deerfield, EcoR1 Capital,
Flagship pioneering, GV, Jennison associates, Khosla Ventures, Omega
funds, Polaris partners, T. Rowe Price, Third Rock Ventures, Viking Global
Investors)
Flagship Pioneering 57.00 Chicago, Illinois USA 1981 750.00 Early Stage, Late Stage Software, Medical Technology, Human Capital Tech, IOT $2.5M-$10M Athersys Inc. - $9M Post-IPO Equity with 2 other investors (Piper Jaffray
Capital Investment Group & First Analysis) in March 2012, and $13.1M Post
Equity IPO in January 2011 with 1 other investor (William Blair)
Forbion Capital Partners 183.00 Cambridge, Massachusetts USA 2000 0.00 Early Stage, Late Stage, Private Equity, Debt Financing Biotechnology, Healthcare, Software Unknown Editas Medicine - $120M (Series B) in Aug, 2015 with 14 other investors
(Boris Nikolic, Alexandria Venture, Casdin Capital, Deerfield, EcoR1 Capital,
Fidelity Management and Research Company, GV, Jennison Associates,
Khosla Ventures, Omega funds, Polaris partners, T. Rowe Price, Third Rock
Ventures, Viking Global Investors)
Formation 8 47.00 Naarden, Noord-Holland Netherlands 2007 500.00 Early Stage, Late Stage Biotechnology, Healthcare, Medical Unknown Bluebird Bio - $60M (Series D) in Jul, 2012 from 6 other Investors (RA
Capital Management, Deerfield Partners, Third Rock Ventures, ARCH
Venture Partners, TVM Capital, Ramius Advisors); Bluebird Bio - $30M
(Venture) in Apr, 2011 from 4 other Investors (Third Rock Ventures, TVM
Capital, Easton Capital, ARCH Venture Partners); Bluebird Bio - $35M(Series
B) in Mar, 2010 from 4 other Investors (TVM Capital, Easton Capital, Third
Rock Ventures, Sanofi-Genzyme BioVentures)
F-Prime Capital Partners 122.00 San Francisco, California USA 2011 0.00 Seed, Early Stage, Late Stage Software, Analytics, ECommerce Unknown Color Genomics $15M Series A in April 2015 with 13 other investors (Angels,
Aaron Levie, AME Cloud Ventures, Drew Houston, Julia Hartz, Katie
Stanton, Khosla ventures, Laurene Powell Jobs, Mariam Naficy, Max Levchin,
Padmasree Warrior, Raymond Tonsing, Ruchi Sanghvi)
GE Capital Unknown Ottawa, Ontario Canada Unknown 0.00 Early Stage, Late Stage, Private Equity, Debt Financing, Grant Biotechnology, Healthcare, Clean Technology Unknown Cytori - $27M (Debt Financing) in July, 2013 with 2 other Investors (Oxford
Finance Corporation, Silicon Valley Bank)
GE Ventures 116.00 Menlo Park, California USA 2013 0.00 Seed, Early Stage, Late Stage, Private Equity Energy, Healthcare, IT, Manufacturing, Diagnostics Unknown Human Longevity Inc. - $220M Series B with 5 other investors (Illumina,
Amino Capital, Celgene, Draper Fisher Jurvetson, StartUp Health) in April
2016
General Catalyst 484.00 Cambridge, Massachusetts USA 2000 3750.00 Seed, Early Stage, Late Stage Software, Mobile Unknown Color Genomics - $45M Series B in September 2016 with 2 other investors
(Emerson Collective, Khosla Ventures); Elysium Health - $20M (Series B) in
Dec, 2016 with 1 other investor (Robert Nelson)
GV 468.00 Mountain View, California USA 2009 0.00 Seed, Early Stage, Late Stage Technology Unknown Editas Medicine - $120M (Series B) in Aug, 2015 with 14 other investors
(Boris Nikolic, Alexandria Venture, Casdin Capital, Deerfield, EcoR1 Capital,
Fidelity Management and Research Company, Flagship pioneering, Jennison
associates, Khosla Ventures, Omega funds, Polaris partners, T. Rowe Price,
Third Rock Ventures, Viking Global Investors)
Harvest Global Investments 3.00 Central, Hong Kong Island China 2008 0.00 Unknown Medicine, Finance Unknown Hua Medicine - $50M Series C in April 2016
Horizon Ventures 25.00 Los Altos, California USA 1999 150.00 Unknown IT Unknown Unknown
Illumina 13.00 San Diego, California USA 1998 0.00 Early Stage, Late Stage Genetics, Biotechnology, Medical Unknown Human Longevity Inc.: $220M Series B with 5 other investors (Amino
Capital, Celgene, Draper Fisher Jurvetson, GE Ventures, StartUp Health) in
April 2016; Human Longevity Inc.: $80M Series A with 6 other investors
(Bryan Johnson, Celgene, Daniel Curran, Draper Fisher Jurvetson, Synthetic
Genomics, Tan Thay) in March 2014; Helix - $100M (Series A) in August 15
2015 with 3 other investors (Mayo Clinic Ventures, Sutter Hill Ventures,
Warburg Pincus)
Integrale Advisors 1.00 Sunnyvale, California USA Unknown 30.40 Unknown Medical Unknown NuSirt Biopharma - $31.46M Series A in September 2015 with 4 other investors (New Science Ventures, Ninelinvest, S.R.I.W., Vives Fund)
Inventages Capital Investment inc Unknown London, England UK 2000 0.00 Early Stage, Late Stage Biotechnology, E Commerce, Manufacturing Unknown GC-Rise Pharma - $4.74M (Series A) in Jan, 2008
Jennison Associates 21.00 New York, New York USA 1969 0.00 Late Stage, Private Equity Biotechnology, Healthcare Unknown Editas Medicine - $120M (Series B) in Aug, 2015 with 14 other investors
(Boris Nikolic, Alexandria Venture, Casdin Capital, Deerfield, EcoR1 Capital,
Fidelity Management and Research Company, Flagship pioneering, GV,
Khosla Ventures, Omega funds, Polaris partners, T. Rowe Price, Third Rock
Ventures, Viking Global Investors)
Juno Therapeutics 1.00 Seattle, Washington USA 2013 47.00 Unknown Medical, Healthcare Unknown Unknown
Khosla Ventures 486.00 Menlo Park, California USA 2004 0.00 Seed, Early Stage, Late Stage, Private Equity, Debt Financing, Post IPO Clean Technology, Mobile, Software Unknown Color Genomics - $45M Series B in September 2016 with 2 other investors
(General Catalyst (Lead investor), Emerson Collective); Color Genomics $15M
Series A in April 2015 with 13 other investors (Angels, Aaron Levie, AME
Cloud Ventures, Drew Houston, Formation 8, Julia Hartz, Katie Stanton,
Laurene Powell Jobs, Mariam Naficy, Max Levchin, Padmasree Warrior,
Raymond Tonsing, Ruchi Sanghvi); Editas Medicine - $120M (Series B) in
Aug, 2015 with 14 other investors (Boris Nikolic, Alexandria Venture, Casdin
Capital, Deerfield, EcoR1 Capital, Fidelity Management and Research
Company, Flagship pioneering, GV, Jennison associates, Omega funds,
Polaris partners, T. Rowe Price, Third Rock Ventures, Viking Global Investors)
LabCorp 11.00 Burlington, North Carolina USA 1976 0.00 Unknown Unknown Unknown Emulate Inc. - $28M (Series B) in March 2016 with 2 other investors (OS
Fund, ATEL Ventures)
Legend Capital 89.00 Unknown China 2001 0.00 Seed, Early Stage, Late Stage E Commerce, Software, Mobile Unknown Harbour BioMed - $50M (Series A) in Dec, 2016 with 1 other investor
(Legend Capital)
LYZZ Capital 3.00 Unknown China Unknown 0.00 Seed, Early Stage, Late Stage Healthcare Unknown Chipscreen - $7.7M (Venture) in April 2015 from 1 other investor (Vertex
Ventures)
Magic Stone Alternative 27.00 Beijing Beijing, China 2011 1000.00 Late Stage Healthcare, Medical Unknown BGI - $653.86M (Series B) in January 2015
Mayo Clinic Ventures 3.00 Rochester, Minnesota USA Unknown 140.00 Unknown Healthcare, Medical Technology Unknown Helix - $100M (Series A) in August 15 2015 with 3 other investors (Illumina,
Sutter Hill Ventures, Warburg Pincus)
Merck Ventures 26.00 Yavne, HaMerkaz Israel 2009 0.00 Early Stage, Late Stage Biotechnology Unknown Metabomed - "$18M (Series A) in Apr, 2016 with 4 other investors (Arkin Holdings, Boehringer Ingelheim Venture Fund, Pfizer, Pontifax Funds)
Mistletoe 6.00 Tokyo Tokyo, Japan 2013 0.00 Seed, Early Stage, Late Stage Unknown Unknown LPixel Inc. - $7M (Series A) with 2 other investors (JAFCO, Toray Engineering)
NanoDimension 28.00 Grand Cayman, Midland Cayman Islands 2002 0.00 Early Stage, Late Stage, Private Equity Clean Technology, Biotechnology Unknown Emulate Inc. - $12M (Series A) in July 2014 with 1 other investor (Cedar Sinai
Medical Center); Emulate Inc. - $17M (Series B) in October 2016 with 6 other
investors (ALS Finding a Cure, ATEL Ventures, Cedars Sinai Medical Center,
Hansjorg Wyss, NanoDimension, OS Fund, Techammer); SQZ Biotech - $16
Series B with 1 other investor (Polaris Partners) in September 2016
Nazem and Company 1.00 New York, New York USA 1976 0.00 Seed, Early Stage, Late Stage, Pre-IPO Healthcare, Biotechnology, Electronics, IT, Life Sciences Unknown Bluebird Bio - $8.5M (Series A) in June, 2004 with 1 other investor (ABN
AMRO)
New Science Ventures 48.00 New York, New York USA 2004 0.00 Early Stage, Late Stage, Private Equity Biotechnology, Healthcare, Semiconductors Unknown Novadip Biosciences: $31.46M Series A with 4 other investors (Integrale
Advisors, Ninelinvest, S.R.I.W., Vives Fund) in September 2015
Nivelinvest 3.00 Louvain-la-Neuve, Vlaams-Brabant Belgium 2008 0.00 Seed Unknown Unknown Novadip Biosciences: $31.46M Series A with 4 other investors (Integrale
Advisors, New Science Ventures, S.R.I.W., Vives Fund) in September 2015
Odey Asset Management 4.00 London, England UK 1991 140.68 Private Equity Nanotechnology, Venture Capital, Financial Services Unknown Chronos Therapeutics - $12.12M (investment type undisclosed) in December
2013 from 3 other investors (Odey Swan, Testudo Funds, University of
Oxford)
Odey Swan 1.00 London, England UK Unknown 10.10 Venture Therapeutics Unknown Chronos Therapeutics - $12.12M (investment type undisclosed) in December 2013 from 3 other investors (Odey Asset Management, Testudo Funds, University of Oxford)
Omega Funds 27.00 Boston, Massachusetts USA Unknown 0.00 Early Stage, Late Stage, Private Equity Biotechnology, Healthcare, Software, Hardware Unknown Editas Medicine - $120M (Series B) in Aug, 2015 with 14 other investors
(Boris Nikolic, Alexandria Venture, Casdin Capital, Deerfield, EcoR1 Capital,
Fidelity Management and Research Company, Flagship pioneering, GV,
Jennison associates, Khosla Ventures, Polaris partners, T. Rowe Price, Third
Rock Ventures, Viking Global Investors)
OrbiMed 218.00 New York, New York USA 1989 4580.00 Early Stage, Late Stage, Private Equity, Debt Financing, Post IPO Biotechnology, Healthcare Unknown GC-Rise Pharma - $15M (Series B) in Sep, 2014
OS Fund 16.00 New York, New York USA Unknown 0.00 Stages: Venture Computer, Hedge Fund, Operating Systems Unknown Emulate Inc. - $28M (Series B) in March 2016 with 2 other investors
(LabCorp, ATEL Ventures); Emulate Inc. - $17M (Series B) in October 2016
with 6 other investors (ALS Finding a Cure, ATEL Ventures, Cedars Sinai
Medical Center, Hansjorg Wyss, NanoDimension, Techammer)
Oxford Finance Corporation Unknown Alexandria, Virginia USA 2002 0.00 Early Stage, Late Stage, Debt Financing, Post IPO Biotechnology, Healthcare, Wellbeing Unknown Cytori - $27M (Debt Financing) in July, 2013 with 2 other Investors (GE
Capital, Silicon Valley Bank)
Oxford Sciences Innovation 4.00 London, England UK 2015 0.00 Unknown Venture Unknown Evox Therapeutics - $14.43M (Seed) in May 2016
Partners Innovation Fund Unknown Boston, Massachusetts USA 2007 0.00 Seed, Early Stage, Debt Financing Medical Device, Healthcare, IT Unknown Editas Medicine - $43M (Series A) in Nov, 2013 with 3 other investors
(Flagship Pioneering, Polaris Partners, Third Rock Ventures)
Piper Jaffray Private Capital Group 11.00 Saratoga Springs, New York USA 1895 0.00 Late Stage Biotechnology, Curated Web Unknown Athersys Inc. ($9M Post-IPO Equity with 2 other investors (William Blair &
First Analysis) in March 2012
Polaris Partners Unknown Boston, Massachusetts USA 1996 0.00 Seed, Early Stage, Late Stage Healthcare, Technology Unknown Editas Medicine - $120M (Series B) in Aug, 2015 with 14 other investors
(Boris Nikolic, Alexandria Venture, Casdin Capital, Deerfield, EcoR1 Capital,
Fidelity Management and Research Company, Flagship pioneering, GV,
Jennison associates, Khosla Ventures, Omega funds, T. Rowe Price, Third
Rock Ventures, Viking Global Investors); SQZ Biotech - $16M Series B with
1 other investor (NanoDimension) in September 2016; SQZ Biotech - $5M
Series A with 1 other investor (20/20 Healthcare Partners) in June 2015
RA Capital Management 61.00 Boston, Massachusetts USA 2001 0.00 Early Stage, Late Stage, Private Equity, Post IPO Biotechnology, Healthcare Unknown Bluebird Bio - $60M (Series D) in Jul, 2012 from 6 other Investors (Deerfield
Partners, Third Rock Ventures, ARCH Venture Partners, Forbion Capital
Partners, TVM Capital, Ramius Advisors)
Ramius Advisors Unknown New York, New York USA Unknown 0.00 Late Stage, Private Equity Biotechnology, Pharmaceuticals, Hardware, Software Unknown Bluebird Bio - $60M (Series D) in Jul, 2012 from 6 other Investors (RA
Capital Management, Deerfield Partners, Third Rock Ventures, ARCH
Venture Partners, Forbion Capital Partners, TVM Capital)
Sanofi-Genzyme BioVentures 17.00 Cambridge, Massachusetts USA 1994 0.00 Seed, Early Stage, Late Stage Biotechnology, Healthcare, Pharmaceuticals Unknown Bluebird Bio - $35M(Series B) in Mar, 2010 from 4 other Investors (TVM
Capital, Forbion Capital Partners, Easton Capital, Third Rock Ventures)
Shibuya Kogyo 2.00 Kanazawa, Kanagawa Japan 1931 0.00 Venture Biomedical Sciences Unknown Cyfuse Biomedical - $12M (Venture) in Mar, 2015 with 1 other investors
(Cyberdyne)
Silicon Valley Bank Unknown Santa Clara, California USA 1983 0.00 Early Stage, Late Stage, Private equity, Debt Financing Biotechnology, Software Unknown Cytori - $27M (Debt Financing) in July, 2013 with 2 other Investors (GE Capital, Oxford Finance Corporation)
Sino-Alliance International LTD 1.00 Shanghai, Shanghai China Unknown 0.00 Unknown Medical, Life Sciences Unknown Hua Medicine - $50M Series A with 5 other investors (ARCH Venture
Partners, F-Prime Capital Partners, Eight Roads Ventures, Venrock, WuXi
Healthcare Ventures) in September 2011
Soci?t? R?gionale d'Investissement de Wallonie (S.R.I.W) 15.00 Liege Belgium 1979 0.00 Early Stage Biotechnology, Pharmaceuticals, Medical, Life Science Unknown Novadip Biosciences: $31.46M Series A with 4 other investors (Integrale
Advisors, New Science Ventures, Ninelinvest, Vives Fund) in September
2015
Sphera Funds Management 3.00 Tel Aviv, Tel Aviv Israel 2004 149.00 Late Stage Healthcare, Global pharma, Biotech $30M-$80M  GenSight Biologiscs - $36M Series B in Jul, 2015 with 8 other investors (Abingworth',Fidelity Management and Research Company, HealthCap, Index Ventures, Jennison Associates, Novartis Venture Fund, Perceptive Advisors, and Varsant Ventures)
Springboard Capital 1.00 Jacksonville, Florida USA Unknown 0.00 Early Stage Pharmaceuticals Unknown AxoGen - 12.1M Post-IPO Equity in December 2007 with 3 other investors
(Denovo Ventures, Accuitive Medical Ventures and Cardinal Partners)
StartUp Health 166.00 New York, New York USA 2011 0.00 Seed, Early Stage, Equity Crowdfunding Digital Health, Health Technology, Health Innovation $25k-500k Human Longevity Inc. - $220M Series B with 5 other investors (Illumina, Amino Capital, Celgene, Draper Fisher Jurvetson, GE Ventures) in April 2016
Sutter Hill Ventures Unknown Palo Alto, California USA 1964 0.00 Seed, Early Stage, Late Stage, Debt Financing Technology, Software, SaaS Unknown Hua Medicine - $100M (Series A) in August 15 2015 with 2 other investors
(Illumina, Mayo Clinic Ventures)
SWMF Life Science Fund 3.00 Kalamazoo, Michigan USA Unknown 0.00 Seed, Early Stage, Late Stage Biotechnology, Healthcare Unknown Axonia Medical - $2M Seed in June 2014 with 3 other investors (Biosciences Research and Commercialization Center (BRCC), Research Emeritus University of Michigan); $2M Seed in May 2012 with 1 other investor (Ann
Arbor SPARK)
Syno Capital 4.00 New York, New York USA 2015 100.00 Early Stage Biotechnology Unknown ORIGIN - $12.5M Series A in Jun, 2015
ORIGIN - $25M Venture in Jun, 2017
Synthetic Genomics 1.00 La Jolla, California USA 2005 80.00 Unknown Genomics, Medical Unknown Human Longevity Inc. - $80M Series A with 6 other investors (Bryan Johnson, Celgene, Daniel Curran, Draper Fisher Jurvetson, Illumina, Tan Thay) in March 2014
T. Rowe Price 83.00 Baltimore, Maryland USA 1937 0.00 Early Stage, Late Stage, Private Equity Software, SaaS Unknown Editas Medicine - $120M (Series B) in Aug, 2015 with 14 other investors
(Boris Nikolic, Alexandria Venture, Casdin Capital, Deerfield, EcoR1 Capital,
Fidelity Management and Research Company, Flagship pioneering, GV,
Jennison associates, Khosla Ventures, Omega funds, Polaris partners, Third
Rock Ventures, Viking Global Investors)
Tan Thay Unknown Unknown Unknown Unknown 0.00 Unknown Unknown Unknown Human Longevity Inc. - $80M Series A with 6 other investors (Brian Johnson, Celgene, Daniel Curran, Draper Fisher Jurvetson, Illumina, Synthetic Genomics) in March 2014
Techammer Unknown New York, New York USA 2007 0.00 Seed Software, Big Data, Digital Health, Computational Biology, Synthetics Unknown Emulate Inc. - $17M (Series B) in October 2016 with 6 other investors (ALS Finding a Cure, ATEL Ventures, Cedars Sinai Medical Center, Hansjorg Wyss, NanoDimension, OS Fund)
Techno Venture Management 38.00 Boston, Massachusetts USA Unknown 0.00 Venture Bioscience, Lifesciences, Medical, Pharmaceutical Unknown Unknown
Testudo Funds 1.00 Unknown Unknown Unknown 0.00 Unknown Unknown Unknown Chronos Therapeutics - $12.12M (investment type undisclosed) in December 2013 from 3 other investors (Odey Asset Management, Odey Swan, University of Oxford)
The Thiel Foundation 13.00 San Francisco, California USA 2006 0.00 Grant, Seed Healthcare, Technology $200k-$2M Longevity Biotech - $350k Grant in Apr, 2012
Third Rock Ventures 75.00 Boston, Massachusetts USA 2007 0.00 Seed, Early Stage, Late Stage, Private Equity Biotechnology, Healthcare Unknown Bluebird Bio - $60M (Series D) in Jul, 2012 from 6 other Investors A Capital Management, Deerfield Partners, ARCH Venture Partners, Forbion Capital Partners, TVM Capital, Ramius Advisors); Bluebird Bio - $10M (Venture) in Apr, 2011 from 4 other Investors (TVM Capital, Forbion Capital Partners, Easton Capital, ARCH Venture Partners); Bluebird Bio -$35M(Series B) in Mar, 2010 from 4 other Investors (TVM Capital, Forbion Capital Partners, Easton Capital, Sanofi-Genzyme BioVentures); Editas Medicine - $120M (Series B) in Aug, 2015 with 14 other investors (Boris Nikolic, Alexandria Venture, Casdin Capital, Deerfield, EcoR1 Capital, Fidelity Management and Research Company, Flagship pioneering, GV, Jennison associates, Khosla Ventures, Omega funds, Polaris partners, T. Rowe Price, Viking Global Investors)
Toray Engineering Unknown Unknown Unknown Unknown 0.00 Unknown Unknown Unknown Unknown
TVM Capital 97.00 Munich, Bayern Germany 1983 0.00 Early Stage, Late Stage, Private Equity Biotechnology, Healthcare, Software Unknown Bluebird Bio - $60M (Series D) in Jul, 2012 from 6 other Investors A Capital Management, Deerfield Partners, ARCH Venture Partners, Forbion Capital Partners, TVM Capital, Ramius Advisors); Bluebird Bio - $10M (Venture) in Apr, 2011 from 4 other Investors (TVM Capital, Forbion Capital Partners, Easton Capital, ARCH Venture Partners); Bluebird Bio -$35M(Series B) in Mar, 2010 from 4 other Investors (TVM Capital, Forbion Capital Partners, Easton Capital, Sanofi-Genzyme BioVentures); Editas Medicine - $120M (Series B) in Aug, 2015 with 14 other investors (Boris Nikolic, Alexandria Venture, Casdin Capital, Deerfield, EcoR1 Capital, Fidelity Management and Research Company, Flagship pioneering, GV, Jennison associates, Khosla Ventures, Omega funds, Polaris partners, T. Rowe Price, Viking Global Investors)
TYLT Ventures 41.00 Santa Monica, California USA 2013 0.00 Seed Unknown $10k-2.5M Unknown
Venrock 527.00 Palo Alto, California USA 1963 0.00 Seed, Early Stage, Late Stage, Private Equity Fintech, Security, Health IT, Biotechnology, Medical Devices,
Diagnostics
Unknown Hua Medicine - $25M Series B with 1 other investor (Ally Bridge Group) in January 2015; Hua Medicine - $50M Series A with 5 other investors (ARCH Venture Partners, Eight Roads Ventures, F-Prime Capital Partners, Sino- Alliance International Ltd., WuXi Healthcare Ventures) in September 2011
Versant Ventures 248.00 Menlo Park, California USA 1999 0.00 Early Stage, Late Stage, Private Equity, Debt Financing Biotechnology, Healthcare Unknown Inception Sciences: $10M Series A in December 2013
Vertex Ventures Unknown Palo Alto, California USA 2007 0.00 Seed, Early Stage, Late Stage Enterprise, E Commerce, Mobile Unknown Chipscreen - $7.7M (Venture) in April 2015 from 1 other investor (LYZZ
Capital)
Viking Global Investors 18.00 Greenwich, Connecticut USA 1999 0.00 Early Stage, Late Stage Biotechnology Unknown Editas Medicine - $120M (Series B) in Aug, 2015 with 14 other investors (Boris Nikolic, Alexandria Venture, Casdin Capital, Deerfield, EcoR1 Capital Fidelity Management and Research Company, Flagship pioneering, GV, Jennison associates, Khosla Ventures, Omega funds, Polaris partners, T. Rowe Price, Third Rock Ventures)
Vives Fund 5.00 Louvain-la-Neuve, Vlaams-Brabant Belgium 2004 0.00 Seed, Early Stage, Late Stage Mobile, Sports, Product Development Unknown Novadip Biosciences: $31.46M Series A with 4 other investors (Integrale Advisors, New Science Ventures, Ninelinvest, S.R.I.W.) in September 2015
Warburg Pincus Unknown New York, New York USA 1966 0.00 Seed, Early Stage, Late Stage, Private Equity Biotechnology, Software, E Commerce Unknown Helix - $100M (Series A) in August 15 2015 with 3 other investors (Illumina, Mayo Clinic Ventures, Sutter Hill Ventures)
WuXi Healthcare Ventures Unknown Cambridge, Massachusetts USA Unknown 0.00 Early Stage Life Sciences Unknown Hua Medicine - $50M Series A with 5 other investors (ARCH Venture Partners, Eight Roads Ventures, F-Prime Capital Partners, Sino-Alliance International Ltd., Venrock) in September 2011